Oncology

Marshall Posner, MD, detailed the potential for personalized mRNA vaccines to treat patients with various different tumors and what information is still needed.

By not including race as part of the Chronic Kidney Disease-Epidemiology Collaboration equation, Black patients with cancer were more likely to not receive treatment for their disease.

ESMO’s president, Solange Peters, MD, PhD, discussed a handful of key abstracts presented during the 3 Presidential Symposia sessions at the 2021 ESMO Congress.

A phase 2 trial did not find a significant benefit to progression-free survival with regorafenib in patients with advanced or metastatic chrodoma.

CancerNetwork® sat down with Jason Luke, MD, at the 2021 European Society for Medical Oncology Congress to talk about the latest developments in the use of immunotherapy for metastatic disease.

The toxicity profiles of PD-1 and PD-L1 inhibitors displayed unique characteristics when combines with other agents such as chemotherapy, targeted therapy, and immunotherapy.

Data from the Circulating Cell-Free Genome Atlas on Clinical limit of detection, or cLOD, may help investigators better detect multiple cancers at earlier stages.

The latest episode of CancerNetwork®’s podcast examines an initiative to diversify patient populations in oncology clinical trials and increase accessibility to these opportunities.

Elizabeth Comen, MD, discusses how she balances her love of dance with both her family and her career as a breast cancer oncologist.

Data collected from several large studies of women with breast cancer over the age of 65 years at diagnosis show how frequently certain known pathogenic variants occur in different patient subsets.

Patients with cancer and those without cancer had similar serologic results 6-months after receiving their second BNT162b2 vaccine.

Low study quality was determined in an analysis of real-world studies across multiple drug indications in cancer.

Updates to the National Comprehensive Cancer Network guidelines on the COVID-19 vaccine for patients with cancer indicate that this group should be prioritized for a third dose.

Responses to a cross-sectional survey brought to light disparities through important aspects of diagnosing and treating brain metastases.

Oncomine Dx Target Test is now approved by the FDA as a companion diagnostic for patients with IDH1-mutant cholangiocarcinoma who may be candidates for treatment with ivosidenib.

The VENTANA MMR RxDx Panel is the first FDA-approved companion diagnostic for identifying patients with DNA mismatch repair–deficient solid tumors who might benefit from treatment with dostarlimab-gxly.

Investigators theorize that a filgrastim-sndz biosimilar is an affordable option for patients across a number of tumor types who are undergoing curative intent treatment with chemotherapy and have an intermediate risk for experiencing febrile neutropenia.

A genomic-adjusted radiation dose model can aid in predicting radiotherapy benefit vs physical dose of radiotherapy pan-cancer.

Solid tumors with mismatch repair deficiency that have progressed on or after prior treatment and which have no suitable alternative therapy options may now be treated with dostarlimab following its approval by the FDA.

At a population level, those who were selected for surgery had a greater risk of dying from cancer related causes than dying from non-cancer causes.

The use of belzutifan has been approved by the FDA for patients with cancer that is associated with von Hippel-Lindau disease who do not need immediate surgery.

One in 3 popular cancer articles on social media contain potentially harmful misinformation, according to a report published in the Journal of the National Cancer Institute.

The makers of eflapegrastim received a complete response letter from the FDA due to concerns over manufacturing.

CancerNetwork® sat down with Funda Meric-Bernstam, MD, at the 2021 ASCO Annual Meeting to talk about results of the MyPathway study in HER2-positive advanced solid tumors treated with pertuzumab plus trastuzumab.

Oncologists are trying to remedy the proposed cuts to radiation oncology facilities from the Centers for Medicare and Medicaid Services to lessen health disparities and improve equitable access to care.

Here are some of the important updates from CancerNetwork last week you might have missed in the world of oncology, featuring novel combinations for triple-negative breast cancer, genetic testing for gastrointestinal malignancies, and the FDA approval of belumosudil for chronic graft-versus-host disease.

Take a look at some of the important updates from CancerNetwork last week you might have missed in the world of oncology from the FDA and the journal ONCOLOGY.

Profilin 1, or PFN1, is a key actin-binding protein that is involved in various cellular activities, such as cell motility, survival, and membrane trafficking. By summarizing the functions of PFN1 in cancer, investigators hope to better understand the mechanisms of PFN1 in cancer progression.

This year’s Annual Report to the Nation on the Status of Cancer highlights trends in cancer incidence and mortality overall and in key patient subgroups.

The FDA released a final guidance on evaluating cancer drugs in patients with central nervous system metastases.